These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

623 related articles for article (PubMed ID: 24856119)

  • 1. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS).
    Bockhorn M; Uzunoglu FG; Adham M; Imrie C; Milicevic M; Sandberg AA; Asbun HJ; Bassi C; Büchler M; Charnley RM; Conlon K; Cruz LF; Dervenis C; Fingerhutt A; Friess H; Gouma DJ; Hartwig W; Lillemoe KD; Montorsi M; Neoptolemos JP; Shrikhande SV; Takaori K; Traverso W; Vashist YK; Vollmer C; Yeo CJ; Izbicki JR;
    Surgery; 2014 Jun; 155(6):977-88. PubMed ID: 24856119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.
    Kaufmann B; Hartmann D; D'Haese JG; Stupakov P; Radenkovic D; Gloor B; Friess H
    Dig Surg; 2019; 36(6):455-461. PubMed ID: 30408790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
    Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
    BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended pancreatectomy in pancreatic ductal adenocarcinoma: definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS).
    Hartwig W; Vollmer CM; Fingerhut A; Yeo CJ; Neoptolemos JP; Adham M; Andrén-Sandberg A; Asbun HJ; Bassi C; Bockhorn M; Charnley R; Conlon KC; Dervenis C; Fernandez-Cruz L; Friess H; Gouma DJ; Imrie CW; Lillemoe KD; Milićević MN; Montorsi M; Shrikhande SV; Vashist YK; Izbicki JR; Büchler MW;
    Surgery; 2014 Jul; 156(1):1-14. PubMed ID: 24856668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controversial issues of neoadjuvant treatment in borderline resectable pancreatic cancer.
    Kang CM; Hwang HK; Choi SH; Lee WJ
    Surg Oncol; 2013 Jun; 22(2):123-31. PubMed ID: 23518243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
    Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
    Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS).
    Tol JA; Gouma DJ; Bassi C; Dervenis C; Montorsi M; Adham M; Andrén-Sandberg A; Asbun HJ; Bockhorn M; Büchler MW; Conlon KC; Fernández-Cruz L; Fingerhut A; Friess H; Hartwig W; Izbicki JR; Lillemoe KD; Milicevic MN; Neoptolemos JP; Shrikhande SV; Vollmer CM; Yeo CJ; Charnley RM;
    Surgery; 2014 Sep; 156(3):591-600. PubMed ID: 25061003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
    Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
    Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
    Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
    Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant therapy for localized pancreatic ductal adenocarcinoma.
    Brown ZJ; Shannon AH; Cloyd JM
    Minerva Surg; 2024 Jun; 79(3):315-325. PubMed ID: 38385797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Borderline resectable pancreatic cancer.
    Hackert T; Ulrich A; Büchler MW
    Cancer Lett; 2016 Jun; 375(2):231-237. PubMed ID: 26970276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Shades of Gray" in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria: Debated indications for surgery in pancreatic cancer.
    Lombardi P; Silvestri S; Marino D; Santarelli M; Campra D; De Paolis P; Aglietta M; Leone F;
    Crit Rev Oncol Hematol; 2019 Jan; 133():17-24. PubMed ID: 30661653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
    Hashemi-Sadraei N; Gbolahan OB; Salfity H; O'Neil B; House MG; Shahda S
    Am J Clin Oncol; 2018 Oct; 41(10):982-985. PubMed ID: 28968257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017.
    Isaji S; Mizuno S; Windsor JA; Bassi C; Fernández-Del Castillo C; Hackert T; Hayasaki A; Katz MHG; Kim SW; Kishiwada M; Kitagawa H; Michalski CW; Wolfgang CL
    Pancreatology; 2018 Jan; 18(1):2-11. PubMed ID: 29191513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
    Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
    Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment.
    Takahashi S; Kinoshita T; Konishi M; Gotohda N; Kato Y; Kinoshita T; Kobayashi T; Mitsunaga S; Nakachi K; Ikeda M
    J Hepatobiliary Pancreat Sci; 2011 Jul; 18(4):567-74. PubMed ID: 21331805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial.
    Jang JY; Han Y; Lee H; Kim SW; Kwon W; Lee KH; Oh DY; Chie EK; Lee JM; Heo JS; Park JO; Lim DH; Kim SH; Park SJ; Lee WJ; Koh YH; Park JS; Yoon DS; Lee IJ; Choi SH
    Ann Surg; 2018 Aug; 268(2):215-222. PubMed ID: 29462005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new preoperative prognostic scoring system to predict prognosis in patients with locally advanced pancreatic body cancer who undergo distal pancreatectomy with en bloc celiac axis resection: a retrospective cohort study.
    Miura T; Hirano S; Nakamura T; Tanaka E; Shichinohe T; Tsuchikawa T; Kato K; Matsumoto J; Kondo S
    Surgery; 2014 Mar; 155(3):457-67. PubMed ID: 24462074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.
    Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
    Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modified Appleby procedure for borderline resectable/locally advanced distal pancreatic adenocarcinoma: A major procedure for selected patients.
    Cesaretti M; Abdel-Rehim M; Barbier L; Dokmak S; Hammel P; Sauvanet A
    J Visc Surg; 2016 Jun; 153(3):173-81. PubMed ID: 26775202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.